StreetAlpha.app
Home › Stocks › ENSC

Ensysce Biosciences, Inc. (ENSC)

$0.36
▼ −0.17%
LAST CLOSE · NOV 20

Ensysce Biosciences develops opioid pain medicines designed to resist abuse and overdose, based in La Jolla, California. It last closed at $0.36 on Nov 20, down 0.17% on the day. The next earnings report for ENSC is expected around Mon, Mar 29, 2027, after the close. For the quarter ended Sep 2026, ENSC reported EPS of -$4.52 on revenue of $2.2M, with revenue up 342.4% from a year ago. Over its last 8 reports the stock moved an average of 8.3% the session after earnings. Over the last 12 months ENSC insiders bought $444K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ENSC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ENSC.

Key Stats

Last 12 months
Results
Revenue
$6.2M
+37.9% vs a year ago
Net income
−$91.0M
−1470.4% margin
EPS (diluted)
−$7.51
Operating margin
−1477.0%
−$91.4M operating income
Valuation
Market cap
$7.0M
19.5M shares
P/E
–
No P/E while losing money
Price to sales
1.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.7M
At Sep 30
Shareholder equity
$27.4M
Shares outstanding
19.5M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.5M$3.5MFY2021FY2022: $2.5M$2.5MFY2022FY2023: $2.2M$2.2MFY2023FY2024: $5.2M$5.2MFY2024FY2025: $5.1M$5.1MFY2025

From ENSC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · After the close
Reported EPS
-$4.52
Quarter ended Sep 2026
Year ago EPS
-$1.29
Same quarter last year
Revenue
$2.2M
+342.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.93Dec '24Mar 2025: -$1.39Mar '25Jun 2025: -$0.79Jun '25Sep 2025: -$1.29Sep '25Dec 2025: -$0.56Dec '25Mar 2026: -$0.52Mar '26Jun 2026: -$0.20Jun '26Sep 2026: -$4.52Sep '26Latest -$4.52
Revenue by quarter
Dec 2024: $1.3MDec '24Mar 2025: $1.3MMar '25Jun 2025: $1.4MJun '25Sep 2025: $493,104Sep '25Dec 2025: $1.9MDec '25Mar 2026: $960,999Mar '26Jun 2026: $1.2MJun '26Sep 2026: $2.2MSep '26Latest $2.2M
How ENSC moved after its last 8 reports
Average move the session after a report ±8.3%
Nov 12, 2026After the close+8.1%
Aug 13, 2026After the close+14.8%
May 15, 2026After the close+13.2%
Mar 30, 2026After the close+4.8%
Nov 14, 2025After the close−4.8%
Aug 13, 2025After the close−4.2%
May 13, 2025After the close+11.6%
Mar 10, 2025After the close−4.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ENSCStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ENSC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ENSC

Technical Analysis

ENSC · as of the Nov 20 close · updated each morning
Downtrend

The stock is 8% below its 20 day and 21% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the Pivot S1 at $0.35, and the nearest resistance the Pivot R1 at $0.37.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 12.0%/day
Key levels
$1.8552 week high+413.9%
$0.4450 day average+22.2%
$0.42Swing high (Aug 26)+16.7%
$0.40100 day average+11.1%
$0.40200 day average+11.1%
$0.3920 day average+8.3%
$0.37Pivot R1+2.8%
$0.36Pivot+0.0%
$0.36Last close
$0.35Pivot S1−2.8%
$0.35Swing low (Aug 24)−2.8%
$0.2352 week low−36.1%
Indicators
RSI (14)39.64Weak, oversold below 30Neutral
MACD-0.02Below its signal lineBearish
Stochastic42.3Middle of its rangeNeutral
ADX (14)19.3No clear trend
Williams %R-59.4Oversold below −80, overbought above −20Neutral
CCI (20)-69.0Oversold below −100, overbought above 100Neutral
Rate of change+9.5%Change over 10 sessionsBullish
ATR (14)$0.04Typical daily range, 12.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ENSC

What happened before

See how ENSC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ENSC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ENSC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ENSCHow many large options trades hit ENSC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ENSC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●9 buying vs 10 selling
  • ▲Held by funds +50.3 pts
  • ▲Funds holding +1
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1918+5.6%
In funds' top 1000–
Held by funds55.0%4.7%+50.3 pts
New / increased6 / 35 / 5−10.0%
Reduced / sold out5 / 51 / 2+233.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ENSC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ENSC Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$444K1 buy · 1 insider
Sold$00 sales · 0 insiders
2026-08 bought $444KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 7Bob G GowerDirectorBuy908,614$0.49$444K
Every insider buy and sale for ENSC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ENSC insider trades →

From SEC Form 4 filings by ENSC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENSC is in one of them and how their past ENSC trades turned out.

ENSC in the AI portfolios
Loading…

ENSC News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENSC in an article yet. Here's the latest on the wider market.

ENSC in the news

About Ensysce Biosciences

Ensysce Biosciences is a pharmaceutical company based in La Jolla, California. It is developing pain medicines designed to reduce the risk of opioid misuse, abuse and overdose. Its lead candidate, PF614, is an oxycodone prodrug meant to provide pain relief while resisting abuse by injection, snorting and oral misuse. The company's product candidates are aimed at patients with acute or chronic pain and the prescribers who treat them.

Headquarters
La Jolla, CA